In a study commissioned by PhRMA, Battelle reports that countries around the globe are boosting their investments in R&D and instituting innovation-friendly policies to attract biopharma outfits. PhRMA CEO John Castellani said in a statement that regulatory uncertainty and strict IP laws could put the U.S. at a disadvantage, leading big-earning biopharma companies to flee overseas. Castellani points to Germany, which used to be "the world's medicine cabinet," and cautions that if the U.S. government doesn't reaffirm its commitment to biomedical innovation, it could lose its standing in the industry. Release